Outcomes Following Candiduria in Extremely Low Birth Weight Infants

Department of Pediatrics, Duke University, Durham, NC 27715, USA.
Clinical Infectious Diseases (Impact Factor: 9.42). 12/2011; 54(3):331-9. DOI: 10.1093/cid/cir800
Source: PubMed

ABSTRACT Candidiasis carries a significant risk of death or neurodevelopmental impairment (NDI) in extremely low birth weight infants (ELBW; <1000 g). We sought to determine the impact of candiduria in ELBW preterm infants.
Our study was a secondary analysis of the Neonatal Research Network study Early Diagnosis of Nosocomial Candidiasis. Follow-up assessments included Bayley Scales of Infant Development examinations at 18-22 months of corrected age. Risk factors were compared between groups using exact tests and general linear modeling. Death, NDI, and death or NDI were compared using generalized linear mixed modeling.
Of 1515 infants enrolled, 34 (2.2%) had candiduria only. Candida was isolated from blood only (69 of 1515 [4.6%]), cerebrospinal fluid (CSF) only (2 of 1515 [0.1%]), other sterile site only (not urine, blood, or CSF; 4 of 1515 [0.3%]), or multiple sources (28 of 1515 [2%]). Eleven infants had the same Candida species isolated in blood and urine within 3 days; 3 (27%) had a positive urine culture result first. Most urine isolates were Candida albicans (21 of 34 [62%]) or Candida parapsilosis (7 of 34 [29%]). Rate of death or NDI was greater among those with candiduria (50%) than among those with suspected but not proven infection (32%; odds ratio, 2.5 [95% confidence interval, 1.2-5.3]) after adjustment. No difference in death and death or NDI was noted between infants with candiduria and those with candidemia.
These findings provide compelling evidence that ELBW infants with candiduria are at substantial risk of death or NDI. Candiduria in ELBW preterm infants should prompt a systemic evaluation (blood, CSF, and abdominal ultrasound) for disseminated Candida infection and warrants treatment.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Candidemia is a cause of significant morbidity and mortality in neonates and children. Risk factors for candidemia include prolonged stay in the intensive care unit, prior antibiotic therapy, immunosuppression related to malignancy, transplantation, use of immunosuppressants or steroids, neutropenia, need for mechanical ventilation, use of vasopressors, recent surgery (especially gastrointestinal), intravenous catheters and receipt of total parenteral nutrition. Candida albicans followed by C. parapsilosis are the most common species causing candidemia in children. Clinicians must be aware of the risk factors for candidemia and the local epidemiology of Candida species in order to direct antifungal therapy appropriately. Ongoing efforts to minimize health care-associated candidemia through infection control practices, judicious antimicrobial use and antifungal prophylaxis in appropriate situations are important to reducing Candida-associated morbidity and mortality in neonates and children.
    Current Fungal Infection Reports 12/2012; 6(4). DOI:10.1007/s12281-012-0113-y
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Fungal infections represent a serious problem in neonatal intensive care units (NICUs) worldwide. Preterm infants are a vulnerable population for major events and adverse sequelae from fungal sepsis. The primary fungus of concern in neonates is C. albicans, whose colonization is associated with devastating complication and high rate of mortality. Among the risk factors responsible for development of invasive fungal infections, previous mucosal and skin colonization are of primary importance. Fungal colonization in neonates may be secondary to either maternal transmission or nosocomial acquisition in the nursery. Antifungal prophylaxis is currently applied in different NICUs and in various patients groups with successful results. Prophylactic drugs can include oral nystatin and oral or intravenous fluconazole. To date, antifungal prophylaxis with fluconazole is the recommended approach for neonates lower than 1,000 g and/or 27 weeks' gestation or less, manly in NICUs with relatively high frequency of invasive candidiasis. First-line treatment of invasive fungal infections includes amphotericin B deoxycholate, lipid preparations of amphotericin B, fluconazole, or micafungin. However, data on pharmacokinetic, schedule treatment and appropriate dosage of antifungal agents in neonates, mainly in premature, are still limited. Future strategies to reduce neonatal morbidity and mortality derived from invasive fungal infections include new echinocandins not yet approved Proceedings of the 10 th International Workshop on Neonatology · Cagliari (Italy) · October 22
  • [Show abstract] [Hide abstract]
    ABSTRACT: Objective Systemic fungal infections are major causes of morbidity and mortality, and are associated with significant neurodevelopmental impairment in premature infants. Our objective was to evaluate the efficacy of fluconazole prophylaxis in prevention of systemic fungal infections among preterm infants. Study Design This observational pre-post cohort study was performed in preterm infants with a birth weight of < 1,000 g who were given prophylactic fluconazole starting on the first postnatal day at a dose of 3 mg/kg twice a week. These infants were compared with preterm infants who were not given prophylaxis. Results Prophylaxis group consisted of 90 infants and control group consisted of 107 infants. Systemic fungal infection was observed in five patients (4.7%) in the control group while no fungal infection was detected in the prophylaxis group (p = 0.03). There were no significant differences between two groups in terms of demographic features, maternal and neonatal risk factors, and all-cause mortality rates. No adverse reactions were seen during the prophylaxis period. Conclusions We suggest that intravenous fluconazole prophylaxis at a dose of 3 mg/kg twice a week is a safe and effective strategy for decreasing systemic fungal infections even in neonatal intensive care units with low rates of invasive Candida infection.
    American Journal of Perinatology 02/2014; 31(12). DOI:10.1055/s-0034-1371358 · 1.60 Impact Factor

Full-text (2 Sources)

Available from
Jun 1, 2014